Allygen Biologics

Explore the latest insights on Allygen Biologics and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Allygen Biologics’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

AstraZeneca's Q3 Revenue Rises 7% to USD 16.21 Billion as Oncology Surges 17% and China Sales Rebound 9%
Company

AstraZeneca’s Q3 Revenue Rises 7% to USD 16.21 Billion as Oncology Surges 17% and China Sales Rebound 9%

AstraZeneca plc (NYSE: AZN) reported third‑quarter 2026 worldwide revenue of USD 16.21 billion, up 7% year‑on‑year, driven by strong growth in oncology, respiratory and immunology, and rare disease treatments. The…

*Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal

Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1
CompanyDeals

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1